© Copyright – SPP 2306 | Privacy Policy | Webdesign: Science Crunchers
Our most recent collaborative review with following partners as well as applicants for the 2nd funding period of the SPP 2306
Carsten Berndt, Hamed Alborzinia, Jan P. Böttcher, Simone Brabletz, Thomas Brabletz, Bernhard Brüne, Julia Esser-von Bieren, Maria Fedorova, José Pedro Friedmann Angeli, Manuel A. Friese, Dominic C. Fuhrmann, Ana J. García-Sáez,Magdalena Götz, Linda Hammerich, Aicha Jeridi, David B. Konrad, Andreas Linkermann, Tom Lüdde, Axel Methner, Martina Muckenthaler, Almut Schulze, Andreas Trumpp, Vivek Vikantaramani, Silvia von Karstedt, Frank Westermann, Marcus Conrad
Original publication:
Ferroptosis in Health and Disease
Carsten Berndt, Hamed Alborzinia, Vera Skafar Amen, Scott Aytone, Uladzimir Barayeu, Alexander Bartelt, Hülya Bayir, Christina M. Bebber, Kivanc Birsoym, Jan P. Böttcher, Simone Brabletz, Thomas Brabletz, Ashley R. Brown, Bernhard Brüne, Giorgia Bulli, Alix Bruneau, Quan Chent, Gina M. DeNicolau, Tobias P. Dick, Ayelén Distéfano, Scott Dixon, Jan Broder Engler, Julia Esser-von Bieren, Maria Fedorova, José Pedro Friedmann Angeli, Manuel A. Friese, Dominic C. Fuhrmann, Ana J. García-Sáez, Karolina Garbowicz, Magdalena Götz, Wei Guae, Linda Hammerich, Behrouz Hassannia, Xuejun Jiang, Aicha Jeridi, Jun Pyo Kang, Valerian E Kagan, David B. Konrad, Stefan Kotschi, Peng Lei, Marlene le-Tertre, Sima Lev, Deguang Liang, Andreas Linkermann, Carolin Lohr, Svenja Lorenz, Tom Lüdde, Axel Methner, Bernhard Michalkeau, Anna V. Milton, Junxia Min, Eikan Mishima, Sebastian Müller, Hozumi Motohashi, Martina Muckenthaler, Shohei Murakami, James A. Olzmann, Gabriela Pagnuss, Zijan Pan, Thales Papagiannakopoulos, Lohans Pedrera Puentes, Derek A. Pratt, Bettina Proneth, Lukas Ramsauer, Raphael Rodriguez, Yoshiro Saito, Felix Schmidt, Carina Schmitt, Almut Schulze, Annemarie Schwab, Anna Schwantes, Mariluz Soul, Benedikt Spitzlberger, Brent R. Stockwell, Leonie Thewes, Oliver Thorn-Seshold, Shinya Toyokuni, Wulf Tonnus, Andreas Trumpp, Peter Vandenabeele, Tom Vanden Berghe, Vivek Vikantaramani, Felix C. E. Vogel, Silvia von Karstedt, Fudi Wang, Frank Westermann, Michele Wölk, Katherine Wu, Xin Yang, Fan Yu, Yilong Zou, and Marcus Conrad
Redox Biology May 24; in press
Ferroptosis is a pervasive non-apoptotic form of cell death highly relevant in various degenerative diseases and malignancies. The hallmark of ferroptosis is uncontrolled and overwhelming peroxidation of polyunsaturated fatty acids contained in membrane phospholipids, which eventually leads to rupture of the plasma membrane. Ferroptosis is unique in that it is essentially a spontaneous, uncatalyzed chemical process based on perturbed iron and redox homeostasis contributing to the cell death process, but that it is nonetheless modulated by many metabolic nodes that impinge on the cells’ susceptibility to ferroptosis. Among the various nodes affecting ferroptosis sensitivity, several have emerged as promising candidates for pharmacological intervention, rendering ferroptosis-related proteins attractive targets for the treatment of numerous currently incurable diseases. Herein, the current members of a Germany-wide research consortium focusing on ferroptosis research, as well as key external experts in ferroptosis who have made seminal contributions to this rapidly growing and exciting field of research, have gathered to provide a comprehensive, state-of-the-art review on ferroptosis. Specific topics include: basic mechanisms, in vivo relevance, specialized methodologies, chemical and pharmacological tools, and the potential contribution of ferroptosis to disease etiopathology and progression. We hope that this article will not only provide established scientists and newcomers to the field with an overview of the multiple facets of ferroptosis, but also encourage additional efforts to characterize further molecular pathways modulating ferroptosis, with the ultimate goal to develop novel pharmacotherapies to tackle the various diseases associated with – or caused by – ferroptosis.
Highlights
- Various disparate metabolic pathways contribute to ferroptosis sensitivity
- Ferroptosis is regulated at the transcriptional and (post)translational levels
- Small molecules readily available to modulate ferroptosis in vitro and in vivo
- Ferroptotic cell death plays a major pathological role in multiple diseases
- Ferroptosis modulation is a promising therapeutic strategy for clinical applications